Trade Mark Journal No.2026/040 2 October 2026
UK00004445536 15 September 2026 (5,10,41,42,44)
- Class 5
- Diagnostic preparations for medical purposes; diagnostic preparations for medical purposes for use in assessing disease progression; diagnostic preparations for medical purposes for testing, detecting, measuring and analysing biomarkers; diagnostic preparations for testing, detecting, measuring and analysing genomic biomarkers, genetic biomarkers, protein biomarkers and metabolomic biomarkers; diagnostic preparations for use with blood, urine and human tissue samples for predicting, identifying, monitoring and determining the presence, risk, progression and stage of diabetes, kidney diseases, diabetic kidney disease and cardiovascular-kidney-metabolic (CKM) syndrome; medical diagnostic blood testing reagents and assays for predicting, identifying and determining the presence and stage of diabetes, kidney diseases, diabetic kidney disease, cardiovascular-kidney-metabolic (CKM) syndrome, and general kidney health; diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing and prediction; test strips for predicting, identifying and determining the presence and stage of diabetes, kidney diseases, diabetic kidney disease, cardiovascular-kidney-metabolic (CKM) syndrome, and for assessing kidney health.
- Class 10
- Medical diagnostic instruments and equipment; blood test collection kit comprised of blood collection bag, holder for medical sample tubes, vials, and test strips, and medical sample tubes and vials for predicting, identifying and determining the presence and stage of diabetes, kidney diseases, diabetic kidney disease, cardiovascular-kidney-metabolic (CKM) syndrome, and general kidney health; urine test kits comprising collection containers, tubes, vials, pipettes, swabs and transport bags for predicting, identifying and determining the presence and stage of diabetes, kidney diseases, diabetic kidney disease, cardiovascular-kidney-metabolic (CKM) syndrome, and general kidney health; human tissue test kit comprising containers, tubes, vials, pipettes, swabs and transport bags for predicting, identifying and determining the presence and stage of diabetes, kidney diseases, diabetic kidney disease, cardiovascular-kidney-metabolic (CKM) syndrome, and general kidney health; parts and fittings for the aforesaid.
- Class 41
- Education and training services in the field of diagnostics, diabetes, kidney diseases, diabetic kidney disease, cardiovascular-kidney-metabolic (CKM) syndrome, and general kidney health; education and training services in the field of biomarkers; providing seminars and workshops in the field of diagnostics, diabetes, kidney diseases, diabetic kidney disease, cardiovascular-kidney-metabolic (CKM) syndrome, and general kidney health; providing seminars and workshops in the field of biomarkers; information and consultancy services in relation to the aforesaid.
- Class 42
- Platform-as-a-Service [PaaS] featuring software platforms for medical analysis; Platform-as-a-Service [PaaS] featuring artificial intelligence, machine-learning or algorithm-based software platforms for medical analysis; Platform-as-a-Service [PaaS] featuring artificial intelligence, machine-learning or algorithm-based software platforms for medical analysis of biomarkers; Platform-as-a-Service [PaaS] services featuring software platforms for analysing biomarkers alone or in combination with multi-modal clinical and non-clinical data, laboratory measurements, demographic information, medication information and patient medical history; Platform-as-a-Service [PaaS] featuring software platforms for analysing, displaying, and reporting medical and diagnostic test results; Platform-as-a-Service [PaaS] featuring software platforms for testing, screening, and monitoring diabetes, kidney diseases, diabetic kidney disease, cardiovascular-kidney-metabolic (CKM) syndrome, and general kidney health; Platform-as-a-Service [PaaS] featuring software platforms for medical diagnosing and prognosticating; Platform-as-a-Service [PaaS] featuring software platforms for monitoring and predicting patient response to treatment options; Platform-as-a-Service [PaaS] featuring software platforms for predicting the presence, risk, progression and stage of diabetes, kidney diseases, diabetic kidney disease and cardiovascular-kidney-metabolic (CKM) syndrome; Platform-as-a-Service [PaaS] featuring risk-based predictive algorithm software for analysing and evaluating the risk of kidney diseases, diabetes, diabetic kidney disease and cardiovascular-kidney-metabolic (CKM) syndrome; Software-as-a-Service [SaaS] featuring software for medical analysis; Software-as-a-Service [SaaS] featuring artificial intelligence, machine-learning or algorithm-based software for medical analysis; Software-as-a-Service [SaaS] featuring artificial intelligence, machine-learning or algorithm-based software for medical analysis of biomarkers; Software-as-a-Service [SaaS] services featuring software for analysing biomarkers alone or in combination with multi-modal clinical and non-clinical data, laboratory measurements, demographic information, medication information and patient medical history; Software-as-a-Service [SaaS] featuring software for analysing, displaying, and reporting medical and diagnostic test results; Software-as-a-Service [SaaS] featuring software for testing, screening, and monitoring diabetes, kidney diseases, diabetic kidney disease, cardiovascular-kidney-metabolic (CKM) syndrome, and general kidney health; Software-as-a-Service [SaaS] featuring software for medical diagnosing and prognosticating; Software-as-a-Service [SaaS] featuring software for monitoring and predicting patient response to treatment options; Software-as-a-Service [SaaS] featuring software for predicting the presence, risk, progression and stage of diabetes, kidney diseases, diabetic kidney disease and cardiovascular-kidney-metabolic (CKM) syndrome; Software-as-a-Service [SaaS] featuring risk-based predictive algorithm software for analysing and evaluating the risk of kidney diseases, diabetes, diabetic kidney disease and cardiovascular-kidney-metabolic (CKM) syndrome; Development of new technology for others in the field of medical devices and medical diagnostic apparatuses and instruments; research, laboratory research in the field of diabetes, kidney diseases, diabetic kidney disease, cardiovascular-kidney-metabolic (CKM) syndrome, and general kidney health; medical research services; research and development services in the field of antibodies.
- Class 44
- Medical diagnostic services; medical prognostic testing services; medical analysis services for diagnosis and prognosis of diabetes, kidney diseases, diabetic kidney disease, cardiovascular-kidney-metabolic (CKM) syndrome, and general kidney health; medical testing services; medical analysis services; medical analysis services for analysing biomarkers; medical analysis services for analysing biomarkers alone or in combination with multi-modal clinical and non-clinical data, laboratory measurements, demographic information, medication information and patient medical history; medical screening services; monitoring of patients; preparation, compilation, and issuing of medical reports; medical diagnostic testing services; medical diagnostic testing using multi-modal data, methods and data observation streams; medical diagnostic testing using multi-modal data, methods and data observation streams for evaluating patients, characterising patient conditions, and evaluating the presence, risk, progression and stage of diabetes, kidney diseases, diabetic kidney disease and cardiovascular-kidney-metabolic (CKM) syndrome; medical profile and medical record analysis designed to provide patients with custom tailored information about the range of possible diagnoses and therapies associated with a defined set of symptoms.
Renalytix AI, Inc.
Representative: Mewburn Ellis LLP